Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | CCKBR | P32239 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836145 | 0.83 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL14068077 | 0.83 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL14068073 | 0.83 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL18194528 | 0.83 | HSD11B1 (0.36) | HSD11B1ACHE | |
| SCHEMBL14068053 | 0.81 | ALDH1A1 (0.39) | HSD11B1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL14068050 | 0.81 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL14068038 | 0.80 | HTR1A (0.42) | — | |
| SCHEMBL14068033 | 0.75 | SIGMAR1 (0.55) | HSD11B1SIGMAR1 | |
| SCHEMBL14068010 | 0.75 | SIGMAR1 (0.55) | HSD11B1SIGMAR1 | |
| SCHEMBL14068009 | 0.72 | SIGMAR1 (0.52) | HSD11B1SIGMAR1EPHX2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563591-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-22 | — | — | US | claimed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | claimed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | claimed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | claimed |
| US-9630921-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-25 | — | — | US | disclosed |
| US-9630921-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-25 | — | — | US | disclosed |
| US-9630921-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-25 | — | — | US | disclosed |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422284-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | disclosed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | disclosed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | CHRM1, CHRNA7, CHRM5 | HSD11B1 136/4885SIGMAR1 191/4885EPHX2 1441/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885SIGMAR1 1227/4885EPHX2 661/4885 |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | HSD11B1 3/4885SIGMAR1 2693/4885EPHX2 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.